The birth pangs of monoclonal antibody therapeutics The failure and legacy of centoxin

Research output: Contribution to journalArticlepeer-review

39 Citations (Scopus)

Abstract

T his paper examines the development and termination of nebacumab (Centoxin (R)), a human IgM monoclonal antibody (mAb) drug frequently cited as one of the notable failures of the early biopharmaceutical industry. The non-approval of Centoxin in the United States in 1992 generated major concerns at the time about the future viability of any mAb therapeutics. For Centocor, the biotechnology company that developed Centoxin, the drug posed formidable challenges in terms of safety, clinical efficacy, patient selection, the overall economic costs of health care, as well as financial backing. Indeed, Centocor's development of the drug brought it to the brink of bankruptcy. This article shows how many of the experiences learned with Centoxin paved the way for the current successes in therapeutic mAb development.

Original languageEnglish
Pages (from-to)403-412
Number of pages10
JournalMabs
Volume4
Issue number3
DOIs
Publication statusPublished - May 2012

Fingerprint

Dive into the research topics of 'The birth pangs of monoclonal antibody therapeutics The failure and legacy of centoxin'. Together they form a unique fingerprint.

Cite this